Sanofi's strategy of defending its position in Pompe disease, a space where the French company's Myozyme/Lumizyme is the only approved therapy, has been kickstarted by the EU filing of avalglucosidase alfa.
The European Medicines Agency has accepted the French major's marketing authorization application for avalglucosidase alfa for long-term enzyme replacement therapy...







